E-mail: kozak@fnkv.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikované knihy
Publikovaná abstrakta
- AML z pohledu morfologie a průtokové cytometrie
- ANALYSIS OF 1458 ACUTE MYELOID LEUKEMIA FROM THE ALERT PROJECT (ACUTE LEUKEMIA CLINICAL REGISTER) IN THE CZECH REPUBLIC IN 1996-2006
- ANALYSIS OF TREATMENT OUTCOME OF ALL PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL): NO DIFFERENCE IN SURVIVAL BEFORE AND AFTER ATRA ERA
- Analýza membránové a relativní genové exprese proteinu tepelného šoku Hsp70 u akutní leukémie.
- ARE FLT3 ITD AND D835 MUTATIONS SUFFICIENT INDICATORS FOR ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA? AN ANALYSIS OF PATIENTS FROM THE CZECH ACUTE LEUKEMIA CLINICAL REGISTER (ALERT)
- Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases
- CLINICAL FINDINGS AND TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: THE ANALYSIS OF THE 1425 PATIENTS INCLUDED IN CZECH LYMPHOMA PROJECT (CLP)
- COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND IMATINIB FOR CHRONIC MYELOID LEUKEMIA: RESULTS FROM CAMELIA REGISTRY
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
- Cyclin D1 mRNA Expression In CLL: a Pilot Study
- Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro
- DELTA EX6, THE NOVEL TRANSACTIVATION-DEFECTIVE SPLICING VARIANT OF TP53, IS DIFFERENTIALLY EXPRESSED IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND CONFERS ACCENTED PROLIFERATIVE PHENOTYPE IN VITRO
- DETECTION OF EBV DNA IN PATIENTS WITH HODGKIN LYMPHOMA IN THE CZECH REPUBLIC: FREQUENCY, QUANTITY IN PLASMA, WHOLE BLOOD AND LYMPH NODE
- Difuzní velkobuněčný B lymfom, charakteristika a léčba, data z registru Kooperativní lymfomové skupiny
- EARLY AND LATE RESPONSE ASSESSMENT WITH FDG-PET AFTER BEACOPP-BASED CHEMOTHERAPY IN ADVANCED-STAGE HODGKIN LYMPHOMA PATIENTS HAS A HIGH NEGATIVE PREDICTIVE VALUE
- Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP)
- Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database
- High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry
- CHARACTERIZATION OF KMT2A (MLL) CHROMOSOMAL BREAKPOINTS
- IDENTIFICATION OF A NOVEL, TRANSACTIVATION-DEFECTIVE SPLICING VARIANT OF P53 GENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chem...
- Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies
- INTENSIVE TREATMENT OF HIGH-RISK AGGRESSIVE B-CELL LYMPHOMAS WITH MEGACHOP-ESHAP-BEAM REGIMEN WITH OR WITHOUT RITUXIMAB: RESULTS OF THREE CONSECUTIVE TRIALS OF CLSG
- INTERIM RESULTS FROM AN INTERNATIONAL, MULTI-CENTER, SINGLE-ARM STUDY EVALUATING THE SAFETY AND EFFICACY OF ROMIPLOSTIM IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
- Kooperativní lymfomová skupina (Czech Lymphoma Study Group)
- Léčba novými léky (Velcade, Thalidomid) - zkušenosti s organizací péče o nemocné s mnohočetným myelomem
- Léčba periferních T-nehodgkinských lymfomů v České republice
- Léčba skupiny extraoseálních nádorů Ewingova sarkomu a PNET (periferní neuroektodermový tumor) dle protokolu EURO-E.W.I.N.G 99 u dospělých nemocných.
- LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group
- LOW-DOSE FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINED WITH RITUXIMAB IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PROJECT Q-LITE OF CZECH CLL STUDY GROUP
- Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
- Lymfom z plášťových buněk - od zpřesnění diagnostiky k hledání účinné terapie
- Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic
- Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project
- MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy
- Model klinického registru umožňujícího hodnocení léčebné péče: projekt ALERT (Akutní LEukémie – klinický RegisTr)
- Molecular Variability of FLT3/ITD Mutants and Their Impact on the Differentiation Program of 32D Cells: Implications for the Biological Properties of AML Blasts
- Mutation JAK2 V617F in Patients with Myeloproliferative Disorders and Technical Aspects of Its Detection
- NEXT-GENERATION SEQUENCING AS A TOOL FOR ASSESSING MINIMAL RESIDUAL DISEASE IN AML PATIENTS WITH CEBPA MUTATIONS
- Nové a fenotypicky neobvyklé varianty genu p53 u pacientů s chronickou lymfocytární leukémií
- Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An Internatio
- Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma
- POSITIVE PRETRANSPLANTATION POSITRON EMISSION TOMOGRAPHY INDICATES POOR PROGNOSIS IN RELAPSED HODGKIN LYMPHOMA PATIENTS
- Přehled léčebné strategie u Hodgkinova lymfomu
- QUANTITATION OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED FLUORESCENTLY LABELED PROBES AND REAL-TIME PCR TECHNOLOGY
- Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using LNA-Modified Fluorescently Labeled Probes and Real-Time PCR Technology.
- Randomizovaná studie léčby mladých nemocných s nízce rizikovým difúzním velkobuněčným B lymfomem (DLBCL) s nízkým a srovnávající CHOP-like režim s rituximabem nebo bez rituximabu, (Mabthera International Trial, MInT). První analýza kompletní studie.
- RAPID DETECTION AND IDENTIFICATION OF PATHOGENS IN HEMATOONCOLOGICAL PATIENTS USING MOLECULAR TECHNIQUES
- REDUCED HOSPITALIZATIONS AND BLEEDS IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ROMIPLOSTIM IN CLINICAL PRACTICE – INTERIM RESULTS FROM A LARGE, EUROPEAN, OBSERVATIONAL STUDY
- Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
- RITUXIMAB SIGNIFICANLY IMPROVES THE OUTCOME OF YOUNG POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA - ON BEHALF OF CZECH LYMPHOMA STUDY GROUP
- ROMIPLOSTIM FOR THE TREATMENT OF ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE - INTERIM RESULTS FROM A LARGE, EUROPEAN, OBSERVATIONAL STUDY
- Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study
- Sledování spermatogeneze u mužů s Hodgkinovým lymfomem pomocí průtokové cytometrie
- SPLENECTOMY IN THE TPO MIMETIC ERA – STILL REASONABLE APPROACH?
- Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on B
- SUBJECTIVE OUTCOME (QUALITY OF LIFE) IN LONG-TERM SURVIVORS OF HODGKIN´S LYMPHOMA (HL): A CROSS-SECTIONAL STUDY OF PATIENTS TREATED 1995 TO 2003 WITHIN THE GHSG TRIALS IN THE CZECH REPUBLIC
- The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
- THE TREATMENT MODIFICATION DOES NOT SEEM TO CHANGE THE DLBCL PATIENT´S OUTCOME WHEN CORRELATED WITH EARLY PET RESULTS
- Thrombocytosis over 800 x 109/L Following the Use of Pegfilgrastim after Chemotherapy R-MegaCHOP in Patients with Diffuse Large B-Cell Lymphoma
- TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 2,435 CONSECUTIVE CLL SAMPLES
- Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.
- UPDATED RESULTS FROM A LARGE, OBSERVATIONAL STUDY OF PATIENTS (PTS) WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ROMIPLOSTIM IN EUROPEAN CLINICAL PRACTICE
Články v Klinické onkologii
- Hodnocení FDG PET nálezů na plicích po léčbě Hodgkinova lymfomu.
- Hodnocení mukosity u pacientů léčených vysokodávkovanou chemoterapií s podporou autologních krvetvorných buněk a jeho význam pro odhad perorálního příjmu a dalších faktorů morbidity a mortality
- Indikace k alogenním a autologním transplantacím krvetvorných buněk. Doporučení České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP.
- Léčba Hodgkinovy choroby v roce 2002
- Léčba pacientů s relabovaným/refraktérním Hodgkinovým lymfomem
- Léčba relabovaného a refrakterního Hodgkinova lymfomu – doporučení české studijní skupiny Hodgkinův lymfom
- Model populačního klinického registru umožň ujícího hodnocení léčebné péče: projekt ALERT (akutní leukemie-klinický registr)
- Onkologické riziko: kouření
- Poškození kognitivních funkcí po chemoterapii u pacientů s Hodgkinovým lymfomem – patofyziologie a rizikové faktory
- Význam klinického registru nemocných s lymfomy – přínos, možnosti a limitace
Léčebné postupy
- Léčba relabovaného a refrakterního Hodgkinova lymfomu – doporučení české studijní skupiny Hodgkinův lymfom
- Léčebná doporučení pro chronickou lymfocytární leukémii (CLL)
- Minimální doporučená léčebná strategie u chronické lymfatické leukémie (CLL)
- Minimální doporučená léčebná strategie u nejčastějších hematologických malignit
